Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors. The company was incorporated in 2016 and is headquartered in Oslo, Norway.
Frequently asked questions
What sector does Zelluna ASA (ZLNA) operate in?
Zelluna ASA belongs to the Other sector and operates in the Biotechnology industry.
What is Zelluna ASA (ZLNA) current stock price?
As of the latest data, Zelluna ASA stock price is NOK 20.60, with a previous close of NOK 21.20. Zelluna ASA lost -NOK 0.60 in the last trading session, representing a -2.83% loss.
What is Zelluna ASA (ZLNA) current market capitalization?
Zelluna ASA market cap is approximately 605.92 million.
What is Zelluna ASA (ZLNA) Earnings Per Share (EPS)?
The trailing EPS is -NOK 7.50, and the forward EPS is -NOK 7.80.
Does Zelluna ASA (ZLNA) pay dividends?
No. Zelluna ASA does not pay a dividend.
When is Zelluna ASA (ZLNA) next earnings report?
Zelluna ASA is expected to release its next earnings report on June 30, 2026.
What is Zelluna ASA (ZLNA) beta (volatility) score?
Zelluna ASA has a beta of 0.412, indicating lower volatility than the overall market.
